Improved cancer immunotherapy strategies by nanomedicine.

IF 6.9 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2023-05-01 DOI:10.1002/wnan.1873

Shuai Guo, Jie Feng, Zongheng Li, Sugeun Yang, Xiaozhong Qiu, Yikai Xu, Zheyu Shen

{"title":"Improved cancer immunotherapy strategies by nanomedicine.","authors":"Shuai Guo, Jie Feng, Zongheng Li, Sugeun Yang, Xiaozhong Qiu, Yikai Xu, Zheyu Shen","doi":"10.1002/wnan.1873","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer immunotherapy agents fight cancer via immune system stimulation and have made significant advances in minimizing side effects and prolonging the survival of patients with solid tumors. However, major limitations still exist in cancer immunotherapy, including the inefficiency of immune response stimulation in specific cancer types, therapy resistance caused by the tumor microenvironment (TME), toxicities by the immune imbalance, and short lifetime of stimulator of interferon genes (STING) agonist. Recent advances in nanomedicine have shown significant potential in overcoming the obstacles of cancer immunotherapy. Several nanoscale agents have been reported for cancer immunotherapy, including nanoscale cancer vaccines impacting the STING pathway, nanomaterials reprogramming TME, nano-agents triggering immune response with immune checkpoint inhibitor synergy, ferroptosis-mediated and indoleamine-2,3-dioxygenase immunosuppression-mediated cancer immunotherapy, and nanomedicine-meditated chimeric antigen receptor-T-cell therapy. Herein, we summarize the major advances and innovations in nanomedicine-based cancer immunotherapy, and outline the opportunities and challenges to integrate more advanced nanomaterials into cancer immunotherapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.</p>","PeriodicalId":23697,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"15 3","pages":"e1873"},"PeriodicalIF":6.9000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wnan.1873","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 6

Abstract

Cancer immunotherapy agents fight cancer via immune system stimulation and have made significant advances in minimizing side effects and prolonging the survival of patients with solid tumors. However, major limitations still exist in cancer immunotherapy, including the inefficiency of immune response stimulation in specific cancer types, therapy resistance caused by the tumor microenvironment (TME), toxicities by the immune imbalance, and short lifetime of stimulator of interferon genes (STING) agonist. Recent advances in nanomedicine have shown significant potential in overcoming the obstacles of cancer immunotherapy. Several nanoscale agents have been reported for cancer immunotherapy, including nanoscale cancer vaccines impacting the STING pathway, nanomaterials reprogramming TME, nano-agents triggering immune response with immune checkpoint inhibitor synergy, ferroptosis-mediated and indoleamine-2,3-dioxygenase immunosuppression-mediated cancer immunotherapy, and nanomedicine-meditated chimeric antigen receptor-T-cell therapy. Herein, we summarize the major advances and innovations in nanomedicine-based cancer immunotherapy, and outline the opportunities and challenges to integrate more advanced nanomaterials into cancer immunotherapy. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.

Abstract Image

查看原文本刊更多论文

利用纳米医学改进癌症免疫治疗策略。

癌症免疫治疗药物通过免疫系统刺激对抗癌症，并在减少副作用和延长实体瘤患者生存方面取得了重大进展。然而，肿瘤免疫治疗仍然存在主要的局限性，包括免疫反应刺激在特定类型癌症中的效率低下，肿瘤微环境(tumor microenvironment, TME)引起的治疗抵抗，免疫不平衡引起的毒性，以及干扰素基因刺激剂(STING)激动剂的寿命短。纳米医学的最新进展显示出克服癌症免疫治疗障碍的巨大潜力。一些纳米级药物已经被报道用于癌症免疫治疗，包括影响STING途径的纳米级癌症疫苗，纳米材料重编程TME，纳米药物通过免疫检查点抑制剂协同作用触发免疫反应，铁中毒介导和吲哚胺-2,3-双加氧酶免疫抑制介导的癌症免疫治疗，以及纳米药物介导的嵌合抗原受体- t细胞治疗。在此，我们总结了基于纳米医学的癌症免疫治疗的主要进展和创新，并概述了将更先进的纳米材料整合到癌症免疫治疗中的机遇和挑战。本文分类如下:纳米技术生物学方法>生物学中的纳米系统治疗方法和药物发现>肿瘤疾病的纳米医学治疗方法和药物发现>新兴技术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology NANOSCIENCE & NANOTECHNOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

16.60

自引率

2.30%

发文量

期刊介绍： Nanotechnology stands as one of the pivotal scientific domains of the twenty-first century, recognized universally for its transformative potential. Within the biomedical realm, nanotechnology finds crucial applications in nanobiotechnology and nanomedicine, highlighted as one of seven emerging research areas under the NIH Roadmap for Medical Research. The advancement of this field hinges upon collaborative efforts across diverse disciplines, including clinicians, biomedical engineers, materials scientists, applied physicists, and toxicologists. Recognizing the imperative for a high-caliber interdisciplinary review platform, WIREs Nanomedicine and Nanobiotechnology emerges to fulfill this critical need. Our topical coverage spans a wide spectrum, encompassing areas such as toxicology and regulatory issues, implantable materials and surgical technologies, diagnostic tools, nanotechnology approaches to biology, therapeutic approaches and drug discovery, and biology-inspired nanomaterials. Join us in exploring the frontiers of nanotechnology and its profound impact on biomedical research and healthcare.